Clinical Significance of the Pulmonary Vasodilator Response during Short-term Infusion of Prostacyclin in Primary Pulmonary Hypertension

Circulation

Volumn 93, Issue 3, 1996, Pages 484-488

  Raffy, Olivier ^a   Azarian, Réza ^a   Brenot, François ^a,b   Parent, Florence ^a   Sitbon, Olivier ^a   Petitpretz, Patrick ^a   Hervé, Philippe ^a   Duroux, Pierre ^a   Dinh Xuan, A Tuan ^a   Simonneau, Gérald ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

Epoprostenol; Hemodynamics; Survival

Indexed keywords

PROSTACYCLIN;

ADULT; ARTICLE; HEART CATHETERIZATION; HEART HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SURVIVAL RATE; VASODILATATION;

ADOLESCENT; ADULT; AGED; EPOPROSTENOL; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROGNOSIS; PULMONARY ARTERY; RETROSPECTIVE STUDIES; VASODILATION;

EID: 0030024879     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.93.3.484     Document Type: Article

References (27)

1. Dresdale DT, Schultz M, Michtom RJ. Primary pulmonary hypertension: clinical and hemodynamic study. Am J Med. 1951;11: 686-705.
2. Kriett JM, Kaye MP. The Registry of the International Society for Heart and Lung Transplantation: eighth official report - 1991. J Heart Lung Transplant. 1991;10:491-498.
3. Robin ED. The kingdom of near-dead: the shortened unnatural life history of primary pulmonary hypertension. Chest. 1987;95: 1185-1189.
4. Weir EK. Acute vasodilator testing and pharmacological treatment of primary pulmonary hypertension. In: Fishman AP, ed. The Pulmonary Circulation: Normal and Abnormal: Mechanisms, Management and the National Registry. Philadelphia, Pa: University of Pennsylvania Press; 1990:485-499.
5. Rich S, Martinez J, Lam W, Levy PS, Rosen KM. Reassessment of the effects of vasodilator drugs in primary pulmonary hypertension: guidelines for determining a pulmonary vasodilator response. Am Heart J. 1983;105:119-1277
6. Reeves JT, Groves BM, Turkevich D. The case for treatment of selected patients with primary pulmonary hypertension. Am Rev Respir Dis. 1986;134:342-346.
7. Palevsky HI, Fishman AP. The management of primary pulmonary hypertension. JAMA. 1991;265:1014-1020.
8. 1 treatment of pulmonary hypertension. Am Rev Respir Dis. 1987;136:773-776.
9. Palevsky HI, Fishman AP. Comparison of acute hemodynamic responses to prostacyclin with standard vasodilators in patients with primary pulmonary hypertension. Chest. 1988;93(suppl 3):179S. Abstract.
10. Palevsky HI, Long W, Crow J, Fishman AP. Prostacyclin and acetylcholinc as screening agents for acute pulmonary vasodilator responsiveness in primary pulmonary hypertension. Circulation. 1990;82:2018-2026.
11. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK, Levy PS, Reid LM, Vreim CE, Williams GW. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987; 107:216-223.
12. Weir EK, Rubin LJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM Elliott CG, Fishman AP, Goldring RM, Groves BM, Kernis JT, Koerner SK, Levy PS, Pietra GG, Reid LM, Vreim CE, Williams GW, Wu M. The acute administration of vasodilators in primary pulmonary hypertension (experience from the National Institutes of Health Registry on Primary Pulmonary Hypertension). Am Rev Respir Dis. 1989;140:1623-1630.
13. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984;70:580-587.
14. Brenot F. Primary pulmonary hypertension: case series from France. Chest. 1994;105(suppl):33s-36s.
15. Glanville AR, Burke CM, Theodore J, Robin ED. Primary pulmonary hypertension: length of survival in patients referred for heart-lung transplantation. Chest. 1987;91:675-681.
16. Hughes JD, Rubin LJ. Primary pulmonary hypertension: an analysis of 28 cases and a review of the literature. Medicine. 1986;65: 56-72.
17. Rich S, Levy PS. Characteristics of surviving and non surviving patients in primary pulmonary hypertension. Am J Med. 1984;76: 573-578.
18. Charters AD, Baker W. Primary pulmonary hypertension of unusually long duration. Br Heart J. 1970;32:130-133.
19. Suarez LD, Sciandro EE, Liera JJ, Perosio AM. Long term follow-up in primary pulmonary hypertension. Br Heart J. 1979;41:702-708.
20. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, Levy PS, Pietra GG, Reid LM, Reeves JT, Rich S, Vreim CE, Williams GW, Wu M. Survival in patients with primary pulmonary hypertension: results from a national prospective study. Ann Intern Med. 1991;115:343-349.
21. Rich S, Brundage BH. Primary pulmonary hypertension: current update. JAMA. 1984;251:2252-2254.
22. Rozkovec A, Montanes P, Oakley CM. Factors that influence the outcome of primary pulmonary hypertension. Br Heart J. 1986;55: 449-458.
23. Kanemoto N, Sasamoto H. Pulmonary hemodynamics in primary pulmonary hypertension. Jpn Heart J. 1979;20:395-405.
24. Rich S. Primary pulmonary hypertension. Prog Cardiovasc Dis. 1988;31:205-237.
25. Palevsky HI, Schloo BL, Pietra GG, Weber KT, Janicki JS, Rubin E, Fishman AP. Primary pulmonary hypertension: vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation. 1989;80:1207-1221.
26. Rich S, Brundage BH, Levy PS. The effect of vasodilator therapy on the clinical outcome of patients with primary pulmonary hypertension. Circulation. 1985;71:1191-1196.
27. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.